Extensive studies have tested the clinical impact of double and triple sequential transplants as front-line therapy in MM, following the suggestion that dose escalation can overcome the marked drug resistance characteristic of this disease, but the superiority of such approaches vs one single transplant has still to be demonstrated. The aim of our study was to evaluate the feasibility and efficacy of high-dose idarubicine intensification of a standard busulphan-melphalan conditioning regimen in MM. Twenty-eight patients (median age 55 years) with sensitive disease received PBSCT after high-dose idarubicine combined with busulphan and melphalan and followed by s.c. rhG-CSF until PMN recovery. The most severe toxicity was represented by oral mucositis which resolved with hemopoietic reconstitution. Overall response and CR rate were 52% and 40%, respectively. Currently, 36 patients are alive and 19 are progression-free a median of 20 months (12-36) from transplant. The 3-year projected probability of progression-free survival for patients transplanted after first-line treatment is 60%. The combination of Ida/Bu/Melph appears a promising alternative regimen for PBSCT in myeloma, with low transplant-related toxicity and fast hematological recovery. Long-term followup and a prospective randomized study, now ongoing, will probably clarify whether an idarubicine-intensified regimen will result in superior outcomes to conventional conditioning and even be comparable to a double consecutive transplant program. Bone Marrow Transplantation (2000) 26, 1045-1049.
cal outcome, and multiple myeloma remains a fatal neoplasm due to the marked drug resistance of tumor cells to standard chemotherapy. [3] [4] [5] [6] The use of high-dose therapy followed by stem cell support has demonstrated an increased incidence of complete remission (CR) in single-arm studies. [7] [8] [9] [10] A recent study from the French group on 200 newly diagnosed MM patients has demonstrated the superiority of autologous transplantation vs standard chemotherapy in terms of response rate and survival. 11 Moreover, the wide use of peripheral blood-derived stem cell precursors, [12] [13] [14] [15] which is associated with low transplant-related toxicity, has allowed this approach to be extended to patients up to 70 years of age, and has permitted the use of double or triple transplants with high-dose melphalan as conditioning. [16] [17] [18] Following the impressive results reported by De Witte and colleagues in the allogeneic and autologous transplant setting, [19] [20] [21] [22] we chose to intensify the conditioning regimen by adding high-dose idarubicine to a standard busulphanmelphalan regimen previously utilized in our Institution in autografting MM patients. 23 We wished to evaluate the feasibility and safety of such an approach and the possible impact on long-term outcome.
Patients and methods

Patients
Between February 1997 and January 1999, 28 patients age 39-69 (median 55 years) with multiple myeloma were enrolled in the autologous peripheral blood stem cell transplantation program. Data were analyzed as of 30 January 2000. The study design was approved by the local Subject Protection Committee. Written informed consent was obtained from all patients.
The diagnosis of multiple myeloma was made using the criteria and staging of Durie and Salmon. Patients with major cardiac, pulmonary, neurologic, hepatic disease, or a Karnofsky performance score Ͻ70% were excluded from the program. Fifteen patients were men and 13 women. Paraproteins were detected in all patients: IgG in 16, IgA in 10, light chains in two. At diagnosis, six patients were DurieSalmon IA, 6 IIA, 16 IIIA. Before treatment, 16 patients had extensive lytic bone lesions on radiograph.
Eighteen patients were autografted after primary treat-ment, eight after second-line therapy and two after thirdline therapy. Pre-transplant chemotherapy included melphalan in 12 cases and the DAV regimen (vincristine, doxorubicine, dexamethazone) in 16 cases. Clinical characteristics and details of the treatment of patients in study are shown in Table I . At the time of transplantation five patients were already in CR following pre-transplant chemotherapy; 20 patients were in partial remission (PR) defined as a reduction in the monoclonal component of more than 25% in eight cases, 50% in five cases and 75% in seven cases. Three patients (stage IA, IIA, IIA at diagnosis) did not show a significant reduction in the paraprotein at the time of pre-transplant evaluation.
Mobilization and conditioning regimen
Autologous blood progenitor cells were collected in three patients with cyclophosphamide (Cy) 7 g/m 2 as single infusion on day 1, while 25 patients received Cy 1.2 g/m 2 on days 1, 3 and dexamethazone 40 mg on days 1 to 4. All patients received daily subcutaneous rhG-GSF 5 g/kg administered until completion of stem cell collection. The optimal timing for PBSC collection was determined by daily evaluation of circulating CD34 ϩ cells. Leukapheresis was started when the blood CD34 ϩ cells rose to Ͼ10/l and continued until the target of 2 ϫ 10 6 /kg/body weight was achieved. All procedures were performed using the 
Supportive care
On day ϩ1 from PBSCT, rhG-CSF was started at a dose of 5 g/kg/day and continued until granulocyte count exceeded 1 ϫ 10 9 /l for 2 consecutive days. All patients were nursed in a double room, in a general hematological ward. Prophylactic oral ciprofloxacin and intravenous acyclovir (15 mg/kg) were given routinely during aplasia. Empirical broad-spectrum antibiotic therapy was instituted for fever Ͼ38.5°C when neutrophils were Ͻ0.5 ϫ 10 9 /l. Intravenous narcotic analgesics were administered for pain due to severe oral mucositis. All blood products were irradiated to 20Gy to prevent graft-versus-host disease.
Response criteria
CR was defined as the disappearance of myeloma protein measured by standard electrophoresis, from both serum and urine, with less than 5% plasma cells in the bone marrow. Immunofixation was not considered.
PR was the reduction of serum and/or urinary monoclonal protein to less than 50% of the pre-transplant value.
For patients in PR, progression was defined as a 50% increase of monoclonal protein above the lowest level achieved, while for patients in CR, relapse was the reappearance of the monoclonal component or an increase of bone marrow plasma cells.
Post-transplant therapy
Maintenance treatment with interferon-alpha (IFN) at a dose of 3 ϫ 10 6 IU s.c three times a week was initiated in 25/27 patients after hematological reconstitution and as soon as restoration of good performance status was registered (median 5 months; range 2-7 months). Reasons for not commencing IFN included one myelodysplasia post-PBSCT and one refusal. Currently interferon treatment has been discontinued in 11 cases, because of disease progression (eight cases), depression (two cases), and anorexia (one case).
Results
Engraftment
Median duration of granulocytopenia (Ͻ0.5 ϫ 10 9 /l) was 12 days (range 8-16); 27/28 patients were already granulocytopenic on the day of PBSC reinfusion. The median number of days to reach a granulocyte (PMN) count of 0.1 ϫ 10 9 /l and 0.5 ϫ 10 9 /l was 9 (range 8-13) and 11 (range 9-15) respectively, and to a platelet (PLTS) count of 20 ϫ 10 9 /l it was 13 (range 7-271). The wide range reported for platelet recovery is due to the observation of a single patient who showed extremely delayed platelet reconstitution on day ϩ271 from PBSCT. One patient is not evaluable for complete engraftment because of toxic death on day ϩ24. By that time she had already repopulated for PMN but not for PLTS.
Early regimen-related toxicity
Cardiotoxic complications were not observed in this study. During profound neutropenia, 27 out of 28 patients (96%) developed fever: 11 responded to antibacterial treatment while one patient with pneumonia died from acute respiratory distress on day 24 after transplant. In 15 patients, fever only disappeared at neutrophil recovery. Antifungal treatment was only used in one case for catheter-related candidemia. Eighteen bacteremias were documented in 14
Bone Marrow Transplantation patients: gram-positive cocci in 14 cases, gram-negative bacilli in two, polymicrobial bacteremias in the remaining two. In particular, Enterococcus spp. was isolated from the blood in four patients, viridans group Streptococci and Escherichia coli in two patients each, and Enterobacter cloacae in one.
All patients experienced oral mucositis: according to WHO scale, 25 one patient had grade 1, three grade 3 and 24 grade 4. Pain was treated with continuous intravenous infusion of morphine at a dose of 30 mg/day. Nausea and vomiting were present in 11/28 cases and diarrhea in 6/28 (WHO 2-3). One single case suffered from severe pharingeal bleeding, treated with platelet support and prednisone until recovery.
These toxicities were reversible in all patients and resolved with hematological reconstitution.
Outcome
Twenty-seven patients surviving more than 3 months post transplant were evaluated for response by skeletal radiographs, urine and serum electrophoresis and bone marrow aspirate. Five patients already in CR pre-PBSCT remained in continuous CR. Out of two patients who had stable disease following pre-transplant chemotherapy, one achieved a PR and one remained with stable disease. Among the 20 patients transplanted who had responsive disease within 25 and 75%, nine achieved CR, two obtained a PR (defined as 50% reduction of pre-transplant monoclonal component) and nine did not show a decrease in the monoclonal component. Overall response rate and CR rate were 52% and 40%, respectively.
At present, 26 patients are alive and 19 are progressionfree with a median follow-up of 20 months (12-36) from transplant. Eight patients have relapsed after a median of 20 months (range 12-33) from transplant. The three-year projected probability of survival for patients transplanted after first-line treatment is 60% (Figure 1 ).
Discussion
The use of anthracyclines to intensify treatment in multiple myeloma has already provided encouraging responses. 26 Thus, in the autologous transplant setting the addition of high-dose idarubicine to a standard busulphan-melphalan regimen could represent an interesting alternative to multiple sequential high-dose therapy programs.
In our study, the choice of utilizing high-dose idarubicine by continous infusion was supported by the experience of Jerjis et al, 22 who evaluated the feasibility of high-dose idarubicine with TBI/busulphan and cyclophosphamide in the autologous BMT setting. Over the last 10 years they have optimized a schedule which includes idarubicine 42 mg/m 2 by continous i.v. infusion for 48 h from day Ϫ12 before transplant followed by the busulphan-cytoxan regimen, and the results obtained in 17 patients with AML in 1st CR were compared with an historical control group of 13 patients treated with the standard busulphan-cytoxan regimen. The authors conclude that intensification of the conditioning regimen is feasible and may result in a pro- longation of DFS and OS of this patients' group, although these data need to be confirmed on a larger number of cases in randomized studies.
In our patient population we decided to modify a standard busulphan-melphalan conditioning regimen, employed in our Institution for myeloma patients, by the addition of high-dose idarubicine on days Ϫ9 to Ϫ8, 48 h before the start of busulphan. Since 1997 we have enrolled 28 patients; in all cases the high-dose regimen was well tolerated and no cardiological toxicity was reported.
The main toxicity of our regimen was severe mucositis which occurred in all patients and required intensive supportive measures and analgesia with opioid compounds. Such toxicity may be avoided infusing idarubicine on day Ϫ12, allowing the clearance of the active metabolite idarubicinol by the time of stem cell reinfusion. 22 For this reason we are now evaluating this new mode of administration in a randomized pilot study of idarubicine/busulphan/ melphalan vs busulphan/melphalan.
Despite the prolonged profound neutropenia and the high incidence of fever in our patient population, infectionrelated death occurred in only one patient and antifungal treatment was required in only one case of catheter-related candidemia. The etiology of bacteremias may be presumed to be spread from the oral mucosa and the gastrointestinal tract and confirms the severity of the chemotherapyrelated mucositis.
Several reports have already demonstrated the existence of a dose-intensity relationship in the treatment of MM patients, 27, 28 for this reason, most authors have concentrated their efforts in trying to ascertain whether a double transplant given as front-line therapy is more effective than late salvage high-dose chemotherapy at the time of relapse. The results of randomized studies so far published seem to show no difference in survival between these two different approaches, 29 moreover, the preliminary results from the French Myeloma Intergroup do not document any difference in response rates between two groups of patients randomly assigned to receive a single or double autotransplant as first-line treatment. 30 Our study, although performed on a small number of patients, supports the feasibility of high-dose idarubicine intensification in association with busulphan and melphalan in multiple myeloma. Longer follow up is needed to clarify if intensification of the conditioning regimen will be superior to a standard protocol, and the randomised study now ongoing in our Institution will give more information about clinical efficacy of this approach in comparison to a double transplant program.
